Tumor News and Research

RSS

Preoperative radiation may enhance treatment response in patients with HR-positive, HER2-negative breast cancer

Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when administered in combination with pembrolizumab (Keytruda) and chemotherapy and led to improved treatment responses prior to surgery, according to the results of the phase II P-RAD clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

11 Dec 2025

Skipping sentinel lymph node biopsy may be safe for some early-stage breast cancer patients

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or survival after a median five years of follow-up, according to results from the BOOG 2013-08 phase III clinical trial, presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

11 Dec 2025

Disrupted genome architecture drives lymphoma development

Cancer isn't just about broken genes-it's about broken architecture. Imagine a city where roads suddenly vanish, cutting off neighborhoods from essential services.

10 Dec 2025

AI turns routine pathology slides into powerful maps of the tumor immune landscape

A large study shows that routine H&E pathology slides contain rich spatial proteomic signals that can be decoded by AI to model the tumor immune microenvironment at population scale. By generating virtual multiplex immunofluorescence images, GigaTIME enables pan-cancer discovery of immune patterns linked to invasion stage, survival, and genomic alterations.

10 Dec 2025

Antibody therapy clears residual multiple myeloma in early trial

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

10 Dec 2025

Dietary restriction boosts antitumour immunity by rewiring T cell metabolism

Dietary restriction reshapes CD8+ T cell metabolism by increasing ketone body–driven acetyl-CoA production, preventing terminal exhaustion and enhancing tumour control in mice. This metabolic reprogramming also boosts responsiveness to PD-1 blockade, suggesting a potential strategy to improve cancer immunotherapy.

10 Dec 2025

AI model improves recurrence risk stratification in HR-positive, HER2-negative breast cancer

An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, HER2-negative breast cancer, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

10 Dec 2025

Machine learning models can help diagnose ALS earlier from a blood sample

Using machine learning models, researchers at Michigan Medicine have identified a potential way to diagnose amyotrophic lateral sclerosis, or ALS, earlier from a blood sample, a study suggests.

10 Dec 2025

Triaptosis could be a promising strategy in the fight against cancer

Cancer remains one of the most critical global public health challenges, exerting profound social, economic, and clinical burdens while limiting gains in human life expectancy.

10 Dec 2025

Study shines new light on how cancer avoids the mitotic stopwatch pathway

When cell division (mitosis) takes too long, it can be a sign that something is wrong with the cells, for example DNA damage or chromosomal instability.

10 Dec 2025

$Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma$

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

Researchers profiled a terminally sterilized probiotic-fermented MFH beverage and identified aporphine alkaloids and flavonoids with favorable predicted ADMET properties. Integrated network pharmacology, molecular docking, and 100-ns MD simulations suggest multi-target engagement of metabolic-inflammatory pathways relevant to obesity and type 2 diabetes.

9 Dec 2025

AI-driven method uncovers genetic interactions that fuel cancer progression

University of South Australia scientists have developed a powerful new way to uncover the genetic interactions that fuel cancer progression, paving the way for earlier and more precise treatments.

9 Dec 2025

Small molecule discovery could open the door to new class of treatments for hard-to-treat cancers

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit a cancer-driving protein long considered impossible to target with drugs - a discovery that could open the door to a new class of treatments for leukemia and other hard-to-treat cancers.

9 Dec 2025

Dietary restriction reprograms cancer-fighting immune cells to enhance anti-tumour immunity

Reducing calorie intake helps cancer-fighting immune cells do their jobs more effectively, reports a study by Van Andel Institute scientists and collaborators.

9 Dec 2025

Highly sensitive CRISPR-based method designed to detect low-frequency cancer mutations

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA circulating in the blood.

9 Dec 2025

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as myeloma and lymphoma, as well as solid tumors.

9 Dec 2025

AI method could help clinicians accurately identify brain tumors and radiation necrosis

While targeted radiation can be an effective treatment for brain tumors, subsequent potential necrosis of the treated areas can be hard to distinguish from the tumors on a standard MRI.

8 Dec 2025

Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, are associated with high rates of death unrelated to cancer relapse-primarily infection-and may be avoidable.

8 Dec 2025

A slow-growing, bone-covered, noncancerous mass named as ossifying spindled and epithelioid tumor

It's not often that a pathologist gets to make a diagnosis that works for the patient by preventing treatment from occurring.

8 Dec 2025

Previous
1
...
51
52
53
54
55
56
57
...
1367
Next

Tumor News and Research

Preoperative radiation may enhance treatment response in patients with HR-positive, HER2-negative breast cancer

Skipping sentinel lymph node biopsy may be safe for some early-stage breast cancer patients

Disrupted genome architecture drives lymphoma development

AI turns routine pathology slides into powerful maps of the tumor immune landscape

Antibody therapy clears residual multiple myeloma in early trial

Dietary restriction boosts antitumour immunity by rewiring T cell metabolism

AI model improves recurrence risk stratification in HR-positive, HER2-negative breast cancer

Machine learning models can help diagnose ALS earlier from a blood sample

Triaptosis could be a promising strategy in the fight against cancer

Study shines new light on how cancer avoids the mitotic stopwatch pathway

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

AI-driven method uncovers genetic interactions that fuel cancer progression

Small molecule discovery could open the door to new class of treatments for hard-to-treat cancers

Dietary restriction reprograms cancer-fighting immune cells to enhance anti-tumour immunity

Highly sensitive CRISPR-based method designed to detect low-frequency cancer mutations

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

AI method could help clinicians accurately identify brain tumors and radiation necrosis

Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause

A slow-growing, bone-covered, noncancerous mass named as ossifying spindled and epithelioid tumor

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News